Neurosciences, Mental Health, and Sensory Organs (NESMOS) Department, Faculty of Medicine and Psychology, Sapienza University, Rome, Italy.
Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189, Rome, Italy.
Clin Drug Investig. 2019 Aug;39(8):713-735. doi: 10.1007/s40261-019-00801-9.
Several second-generation antipsychotics (SGAs) are available in long-acting injectable (LAI) formulations.
To systematically review the effects of the two formulations, Monohydrate and Lauroxil, of Aripiprazole LAI in patients with schizophrenia and bipolar disorder during an acute episode or during maintenance treatment.
On September 18, 2018, we adopted the following search strategy: (aripiprazole OR OPC-14597 OR Abilify) AND (long-acting OR depot OR LAI OR once monthly OR prolonged release OR monohydrate OR lauroxil) on PubMed, Cochrane, Scopus, CINAHL, PsycINFO, and Web of Science to identify randomised controlled trials. Furthermore, we searched the ClinicalTrials.gov site for possible additional studies.
We included 28 papers dealing with randomised assignment of aripiprazole LAI formulations in schizophrenia and bipolar disorder in survival studies after stabilisation, in acute studies, and in head-to-head comparisons. Both monohydrate and lauroxil formulations reduced relapses/recurrences with respect to comparators (placebo or 50 mg once-monthly monohydrate) and improved symptomatology in acute schizophrenia.
Only a small number of studies were included in our review, with widely overlapping samples. While a high proportion of studies were wholly or partly industry-sponsored, their outcomes do not appear to have been affected.
Aripiprazole LAI may to be efficacious in reducing relapse of schizophrenia and bipolar disorder in the long term in stabilised patients and in improving symptoms of schizophrenia during its acute phase, with both monohydrate and lauroxil formulations showing efficacy.
有几种第二代抗精神病药物（SGAs）可制成长效注射剂（LAI）。
系统评价阿立哌唑 LAI 的两种制剂——单水合物和 Lauroxil 在处于急性发作期或维持治疗期的精神分裂症和双相情感障碍患者中的疗效。
2018 年 9 月 18 日，我们在 PubMed、Cochrane、Scopus、CINAHL、PsycINFO 和 Web of Science 上采用了以下搜索策略：（阿立哌唑或 OPC-14597 或 Abilify）和（长效或储库或 LAI 或每月一次或延长释放或单水合物或 Lauroxil），以确定随机对照试验。此外，我们在 ClinicalTrials.gov 网站上搜索了可能的其他研究。
我们纳入了 28 篇论文，涉及阿立哌唑 LAI 制剂在稳定后生存研究、急性研究和头对头比较中用于精神分裂症和双相情感障碍的随机分组。单水合物和 Lauroxil 制剂与对照剂（安慰剂或 50mg 每月一次单水合物）相比，均能减少复发/复发，并改善急性精神分裂症的症状。
我们的综述仅纳入了少数研究，且样本广泛重叠。虽然很大一部分研究是由工业界赞助的，但它们的结果似乎并未受到影响。
在稳定的患者中，阿立哌唑 LAI 可能长期有效减少精神分裂症和双相情感障碍的复发，并在急性发作期间改善精神分裂症的症状，单水合物和 Lauroxil 制剂均显示出疗效。
